MAP2K1 and neoplasm: As predicted by our prior in vitro and in vivo data, the same inhibitor combination (AZD6244/AZD8186) had a marked benefit, when compared with MEK1/2 inhibition alone in WM266.4 xenografts, driving tumor regression and significantly increasing overall survival (Fig. 5A).